Qualified in medicine at Karolinska Institute, Stockholm, Sweden with 30 years in various pharmaceutical and biotech R&D functions including clinical research, pharmacovigilance, regulatory, strategic product development and general management. Held roles at national, European and global level while at Glaxo Smith Kline, Pharmacia, Wyeth and Bristol Myers Squibb. Therapeutic area expertise in infectious diseases and immune oncology. Supported the development and launch of Yervoy (ipilimumab), the first check point inhibitor in oncology. Now responsible for R&D of Oslo and Helsinki based immune oncology company with two technology platforms – adenovirus based gene therapy and RAS mutation peptides, both in phase II.
Honorary Lecturer in drug development at King’s College, London 2005 – 2010. Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom and the Royal Society of Medicine.